Mimura Yoshihisa

ミムラヨシヒサ | Mimura Yoshihisa

Affiliation and department：

Research field (1)： Clinical pharmacy

Research keywords (7)：骨転移 , ウェアラブルデバイス , 前立腺がん , 医療薬学 , 消化管吸収 , transporter , pharmacokinetics

Research theme for competitive and other funds (1)：

2020 - 2024 前立腺がんの新規骨転移予測法の開発-骨密度に着目した研究-

Papers (13)：

Yoshihiko Tasaki, Yosuke Sugiyama, Shuzo Hamamoto, Taku Naiki, Takehiro Uemura, Keisuke Yokota, Daisuke Kawakita, Motoki Nakamura, Ryo Ogawa, Takaya Shimura, et al. Eosinophil may be a predictor of immune-related adverse events induced by different immune checkpoint inhibitor types: A retrospective multidisciplinary study. Cancer medicine. 2023
Yoshihiko Tasaki, Shuzo Hamamoto, Yosuke Sugiyama, Nami Tomiyama, Taku Naiki, Toshiki Etani, Kazumi Taguchi, Nayuka Matsuyama, Yasuhito Sue, Yoshihisa Mimura, et al. Elevated eosinophils proportion as predictor of immune-related adverse events after ipilimumab and nivolumab treatment of advanced and metastatic renal cell carcinoma. International journal of urology : official journal of the Japanese Urological Association. 2023. 30. 10. 866-874
Nami Tomiyama, Yoshihiko Tasaki, Shuzo Hamamoto, Yosuke Sugiyama, Taku Naiki, Toshiki Etani, Kazumi Taguchi, Nayuka Matsuyama, Yasuhito Sue, Yoshihisa Mimura, et al. Hemoglobin and neutrophil levels stratified according to International Metastatic Renal Cell Carcinoma Database Consortium risk predict the effectiveness of ipilimumab plus nivolumab in patients with advanced metastatic renal cell carcinoma. International Journal of Urology. 2023
Yosuke Sugiyama, Taku Naiki, Yoshihiko Tasaki, Yoshihisa Mimura, Toshiki Etani, Yusuke Noda, Satoshi Nozaki, Nobuhiko Shimizu, Rika Banno, Takashi Nagai, et al. GNRI sustainability during one cycle of first-line chemotherapy as a prognostic indicator in patients with metastatic urothelial carcinoma. Oncology. 2023. 101. 4. 224-233
Yoshihisa Mimura, Yosuke Sugiyama, Taku Naiki, Tomoya Kataoka, Yoshihiko Tasaki, Toshiki Etani, Nami Tomiyama, Nayuka Matsuyama, Kunihiro Odagiri, Kazunori Kimura, et al. A rare case of successful pain control in a prostate cancer patient with bone metastasis undergoing hemodialysis by measuring the serum oxycodone level and using an activity tracker. Current Problems in Cancer: Case Reports. 2022. 7

ｍore...

MISC (21)：

三村佳久, 杉山洋介, 小田切州広, 田崎慶彦, 飯田萌子, 木村優花, 伊藤菜浪, 堀田祐志, 内木拓, 惠谷俊紀, et al. Cachexia indexは転移性尿路上皮がん患者の予後予測因子となる. 日本癌治療学会学術集会抄録集. 2023. 61回. O40-1
田崎慶彦, 杉山洋介, 伊藤菜浪, 三村佳久, 飯田萌子, 小田切州広, 木村優花, 堀田祐志, 内木拓, 濱本周造, et al. 好酸球は免疫チェックポイント阻害剤によるirAE発症の予測バイオマーカーとなる. 日本癌治療学会学術集会抄録集. 2023. 61回. MSA O58-3
杉山洋介, 内木拓, 三村佳久, 田崎慶彦, 片岡智哉, 小田切州広, 飯田萌子, 木村優花, 伊藤菜浪, 権田将一, et al. オキシコドンの血中濃度の変化とがん性疼痛との関連性の検討. 日本癌治療学会学術集会抄録集. 2023. 61回. O58-5
永井隆, 内木拓, 杉山洋介, 惠谷俊紀, 清水伸彦, 三村佳久, 野田祐介, 阪野里花, 窪田裕樹, 濱本周造, et al. mGPSは転移性尿路上皮癌患者の治療効果と予後を予測するマーカーである. 日本癌治療学会学術集会抄録集. 2023. 61回. P2-4
伊藤菜浪, 三村佳久, 田崎慶彦, 杉山洋介, 飯田萌子, 小田切州広, 木村優花, 堀田祐志, 日比陽子. ニボルマブの異なる投与スケジュールにおけるirAE発症プロファイルの解析. 日本癌治療学会学術集会抄録集. 2023. 61回. P45-5

ｍore...

Education (2)：

2014 - 2018 Nagoya City University Graduate School of Pharmaceutical Sciences
2008 - 2014 Nagoya City University Medicin Medicin

Work history (4)：

2023/04 - 現在 Graduate school of medical sciences, Nagoya city university Deparment of Clinical Pharmaceutics
2018/04 - 現在 Nagoya City University
2018/09 - 2023/04 Nagoya City University Graduate School of Pharmaceutical Sciences
2018/03 - Nagoya City University Graduate School of Pharmaceutical Sciences

Committee career (1)：

2020/07 - 現在愛知県病院薬剤師会学術教育委員会

Association Membership(s) (3)：

Japanese Society of Hospital Pharmacists , JAPANESE SOCIETY OF PHARMACEUTICAL HEALTH CARE AND SCIENCES , THE PHARMACEUTICAL SOCIETY OF JAPAN

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page